NCT04077736View on ClinicalTrials.gov

Low-dose Recombinant Human IL-2 for the Treatment of Relapsing Polychondritis

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 1, 2019

Primary Completion Date

October 10, 2023

Study Completion Date

October 30, 2023

Conditions
Relapsing Polychondritis
Interventions
DRUG

Interleukin-2

low dose interleukin-2 injected subcutaneously, at a dose of 1 million IU five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).

Trial Locations (1)

100044

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER

NCT04077736 - Low-dose Recombinant Human IL-2 for the Treatment of Relapsing Polychondritis | Biotech Hunter | Biotech Hunter